symbicort
astrazeneca s.p.a. - formoterolo e budesonide - formoterolo e budesonide
sinestic
astrazeneca s.p.a. - formoterolo e budesonide - formoterolo e budesonide
assieme
simesa s.p.a. - formoterolo e budesonide - formoterolo e budesonide
osmohale
pharmaxis europe limited - altri diagnostici - altri diagnostici
budesonide e formoterolo sandoz
sandoz s.p.a. - formoterolo e budesonide - formoterolo e budesonide
nebul ascofar t400
flaem nuova spa - apparecchiature per aerosol
oxis
astrazeneca s.p.a. - formoterolo - formoterolo
ambrotus
epifarma s.r.l - ambroxolo - ambroxolo
ambroxolo almus
almus s.r.l. - ambroxolo - ambroxolo
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).